Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α

被引：73

作者：

Schmidt, M

Hochhaus, A

Nitsche, A

Hehlmann, R

Neubauer, A ^{[1
]}

机构：

[1] Klinikum Phillipps Univ Marburg, Zentrum Innere Med, Abt Hamatol Onkol Immunol, D-35043 Marburg, Germany

[2] Univ Heidelberg, Klinikum Mannheim, Med Klin 3, Heidelberg, Germany

[3] Humboldt Univ, Charite Campus Virchow Klinikum, Klin Innere Med Ms Hamatol & Onkol, Berlin, Germany

来源：

BLOOD | 2001年 / 97卷 / 11期

关键词：

D O I：

10.1182/blood.V97.11.3648

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor (IRF) family, has a potential role in chronic myeloid leukemia (CML). Deletion of ICSBP gene in mice leads to a CML-like syndrome and samples from CML patients exhibited impaired ICSBP expression. The present study found that ICSBP expression correlated with risk features determined by Sokal score in untreated CML (P = .007 for high versus low risk). In addition, analyzing ICSBP expression during interferon-alpha (IFN-alpha) therapy in "good" (n = 27) versus "poor" (n = 15) cytogenetic responders, high ICSBP levels were only observed in "good" responders (P = .0002). Together, these data suggest that ICSBP levels are related to initial presentation of CML and the therapeutic response of CML to IFN-alpha, indicating an important role of ICSBP in CML.

引用

页码：3648 / 3650

页数：3

共 21 条

[1] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].

ALLAN, NC ;

RICHARDS, SM ;

SHEPHERD, PCA .

LANCET, 1995, 345 (8962) :1392-1397

[2] STATs and gene regulation [J].

Darnell, JE .

SCIENCE, 1997, 277 (5332) :1630-1635

[3] AN INTERFERON GAMMA-REGULATED PROTEIN THAT BINDS THE INTERFERON-INDUCIBLE ENHANCER ELEMENT OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I GENES [J].

DRIGGERS, PH ;

ENNIST, DL ;

GLEASON, SL ;

MAK, WH ;

MARKS, MS ;

LEVI, BZ ;

FLANAGAN, JR ;

APPELLA, E ;

OZATO, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (10) :3743-3747

[4] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia [J].

Guilhot, F ;

Chastang, C ;

Michallet, M ;

Guerci, A ;

Harousseau, JL ;

Maloisel, F ;

Bouabdallah, R ;

Guyotat, D ;

Cheron, N ;

Nicolini, F ;

Abgrall, JF ;

Tanzer, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :223-229

[5] Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder [J].

Hao, SX ;

Ren, RB .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (04) :1149-1161

[6] RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA [J].

HEHLMANN, R ;

HEIMPEL, H ;

HASFORD, J ;

KOLB, HJ ;

PRALLE, H ;

HOSSFELD, DK ;

QUEISSER, W ;

LOFFLER, H ;

HOCHHAUS, A ;

HEINZE, B ;

GEORGII, A ;

BARTRAM, CR ;

GRIESSHAMMER, M ;

BERGMANN, L ;

ESSERS, U ;

FALGE, C ;

QUEISSER, U ;

MEYER, P ;

SCHMITZ, N ;

EIMERMACHER, H ;

WALTHER, F ;

FETT, W ;

KLEEBERG, UR ;

KABISCH, A ;

NERL, C ;

ZIMMERMANN, R ;

MEURET, G ;

TICHELLI, A ;

KANZ, L ;

TIGGES, FJ ;

SCHMID, L ;

BROCKHAUS, W ;

TOBLER, A ;

REITER, A ;

PERKER, M ;

EMMERICH, B ;

VERPOORT, K ;

ZANKOVICH, R ;

VONWUSSOW, P ;

PRUMMER, O ;

THIELE, J ;

BUHR, T ;

CARBONELL, F ;

ANSARI, H .

BLOOD, 1994, 84 (12) :4064-4077

[7] Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia [J].

Hochhaus, A ;

Yan, XH ;

Willer, A ;

Hehlmann, R ;

Gordon, MY ;

Goldman, JM ;

Melo, JV .

LEUKEMIA, 1997, 11 (07) :933-939

[8] Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene [J].

Holtschke, T ;

Lohler, J ;

Kanno, Y ;

Fehr, T ;

Giese, N ;

Rosenbauer, F ;

Lou, J ;

Knobeloch, KP ;

Gabriele, L ;

Waring, JF ;

Bachmann, MF ;

Zinkernagel, RM ;

Morse, HC ;

Ozato, K ;

Horak, I .

CELL, 1996, 87 (02) :307-317

[9] Treatment of chronic myelogenous leukemia: Current status and investigational options [J].

Kantarjian, HM ;

OBrien, S ;

Anderlini, P ;

Talpaz, M .

BLOOD, 1996, 87 (08) :3069-3081

[10]

Kreuzer KA, 1999, CLIN CHEM, V45, P297

← 1 2 3 →